Biokey SRL
The score of Biokey shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Total assets -88 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Biokey's annual accounts
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net result | −16,912 € | ||||
| Equity | −220,187 € | ||||
| Cash | 2,036 € | ||||
| EBITDA | −16,797 € | ||||
| Total assets | 2,606 € |
Filed annual accounts
- Year ended 30 Apr 2026filed on 01 Oct 2026
- Year ended 30 Apr 2025filed on 17 Sep 2025
- Year ended 30 Apr 2024filed on 29 Nov 2024
- Year ended 30 Apr 2023filed on 20 Dec 2023
- Year ended 30 Apr 2022filed on 29 Dec 2022
Biokey's financial analysis
- Solvency-8448.4%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Biokey
Biokey's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0719.913.808
- VAT number
- BE0719913808
- Peppol
- Registered · 0208:0719913808 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 06 Feb 2019
- Registered office
- 3590 Diepenbeek
- Latest accounts
- 2026 · filed on 01 Oct 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Biokey (SRL) has been based in Diepenbeek since 2019, active in: research and experimental development on biotechnology. For 2026, it reports a net loss of 16,912 € and equity of −220,187 €; its revenue is not published. Its solvency stands at -8448.4%, below the median of its sector (60.4%).
Companies similar to Biokey
Companies in the same business, of comparable size and area, outside its group.
- Clino Consult Research and experimental development on natural sciences and engineering Beveren-Kruibeke-Zwijndrecht · balance sheet 191,749 €
- ClinInnov Research and experimental development on natural sciences and engineering Ciney · balance sheet 361,049 €
- MDSH Research and experimental development on natural sciences and engineering Ixelles · balance sheet 92,229 €
- Vixen Biosystems Research and experimental development on natural sciences and engineering Ghent · balance sheet €1.19m
- " Akontio " Research and experimental development on natural sciences and engineering Huy · balance sheet 69,650 €
- Europharmedtech Research and experimental development on natural sciences and engineering Ganshoren · balance sheet 54,960 €
- Biograbbit Research and experimental development on natural sciences and engineering Dendermonde · balance sheet 61,503 €
- Strouwen Statistics Research and experimental development on natural sciences and engineering Hasselt · balance sheet 268,681 €
Frequently asked questions about Biokey
What is the revenue of Biokey?
Biokey files its accounts in a format where revenue is optional: it is not published for 2026.
What is the VAT number of Biokey?
In Belgium, the VAT number is the company number prefixed with BE: BE0719913808 for Biokey, if the company is VAT-registered. Its company number (CBE) is 0719.913.808.
Where is the registered office of Biokey?
According to the CBE register, the registered office of Biokey is in 3590 Diepenbeek.
What is the equity of Biokey?
At the close of the 2026 financial year, the equity of Biokey amounts to -220,187 €, a solvency of -8448.4% of total assets.
Who manages Biokey?
The register lists 3 active mandates at Biokey. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Biokey
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →